Anacor Pharmaceuticals, Inc. (ANAC): Anders D Hove , director of Anacor Pharmaceuticals, Inc. sold 229,301 shares on Apr 7, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $72.29 per share for a total value of $16303945.
Company has been under the radar of several Street Analysts.Anacor Pharmaceuticals Inc is Initiated by Mizuho to Buy and the brokerage firm has set the Price Target at $103. The Rating was issued on Mar 11, 2016.
Currently the company Insiders own 4.5% of Anacor Pharmaceuticals Inc shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -2.29%.Institutional Investors own 94.92% of Anacor Pharmaceuticals Inc shares.During last six month period, the net percent change held by insiders has seen a change of -10.66%.
Shares of Anacor Pharmaceuticals Inc (ANAC) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -2.84 points or -4.18% at $65.1 with 10,26,610 shares getting traded. Post opening the session at $68.11, the shares hit an intraday low of $64.97 and an intraday high of $69.15 and the price vacillated in this range throughout the day. The company has a market cap of $2,920 M and the number of outstanding shares has been calculated to be 4,48,58,108 shares. The 52-week high of Anacor Pharmaceuticals Inc is $156.925 and the 52-week low is $52.
Anacor Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on discovering developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company’s product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development which include AN3365. The Company’s compound AN5568 (SCYX-7158) is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).